Simulations Plus (NASDAQ:SLP) Releases Earnings Results, Beats Expectations By $0.19 EPS

Simulations Plus (NASDAQ:SLP - Get Free Report) issued its quarterly earnings data on Monday. The technology company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.19, Zacks reports. Simulations Plus had a return on equity of 7.86% and a net margin of 9.18%. The company had revenue of $20.36 million for the quarter, compared to the consensus estimate of $22.83 million. During the same quarter last year, the business posted $0.27 earnings per share. The firm's revenue was up 9.8% compared to the same quarter last year.

Simulations Plus Stock Performance

NASDAQ SLP traded down $3.39 on Tuesday, reaching $14.08. 1,167,520 shares of the company's stock traded hands, compared to its average volume of 274,575. The firm has a market cap of $283.14 million, a price-to-earnings ratio of 40.39 and a beta of 0.83. The stock has a 50 day moving average price of $24.77 and a 200-day moving average price of $28.37. Simulations Plus has a fifty-two week low of $13.57 and a fifty-two week high of $44.33.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the completion of the transaction, the director directly owned 3,344,157 shares in the company, valued at $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 19.40% of the stock is owned by corporate insiders.

Institutional Trading of Simulations Plus

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Simulations Plus by 26.6% during the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company's stock worth $2,817,000 after purchasing an additional 24,132 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company's stock worth $233,000 after purchasing an additional 390 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Simulations Plus in the 1st quarter valued at approximately $255,000. Finally, Woodline Partners LP boosted its position in Simulations Plus by 32.1% in the 1st quarter. Woodline Partners LP now owns 13,239 shares of the technology company's stock valued at $325,000 after buying an additional 3,220 shares during the period. Hedge funds and other institutional investors own 78.08% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SLP. JMP Securities reiterated a "market perform" rating on shares of Simulations Plus in a report on Wednesday, June 18th. KeyCorp lowered shares of Simulations Plus from an "overweight" rating to a "sector weight" rating in a research note on Tuesday. Stephens cut their price objective on shares of Simulations Plus from $28.00 to $20.00 and set an "overweight" rating for the company in a research report on Tuesday. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Tuesday, June 3rd. Finally, Wall Street Zen raised shares of Simulations Plus from a "sell" rating to a "hold" rating in a report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Simulations Plus has an average rating of "Moderate Buy" and an average price target of $26.50.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.